#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 check­points are deeply en­trenched in the on­col­o­gy mar­ket, it’s time to wel­come a wave of com­bi­na­tion ther­a­pies — be­yond chemo — look­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER